Global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report & Forecast 2022-2028
SKU ID : QYR-20651461 | Publishing Date : 01-Apr-2022 | No. of pages : 103
Detailed TOC of Global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report & Forecast 2022-2028
1 Study Coverage1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Introduction
1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size for the Year 2017-2028
1.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size for the Year 2017-2028
1.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Non-Alcoholic Steatohepatitis (NASH) Drugs in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
1.4.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
1.4.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
1.4.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
1.4.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Non-Alcoholic Steatohepatitis (NASH) Drugs by Type
2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Type
2.1.1 Vitamin E & Pioglitazone
2.1.2 Obeticholic Acid (OCA)
2.1.3 Elafibranor
2.1.4 Selonsertib & Cenicriviroc
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017, 2022 & 2028)
2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028)
2.4 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017, 2022 & 2028)
2.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028)
3 Non-Alcoholic Steatohepatitis (NASH) Drugs by Application
3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Application
3.1.1 Hospital Pharmacy
3.1.2 Online Provider
3.1.3 Retail Pharmacy
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017, 2022 & 2028)
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028)
3.4 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017, 2022 & 2028)
3.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028)
4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Competitor Landscape by Company
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Company
4.1.1 Top Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Ranked by Revenue (2021)
4.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Player (2017-2022)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Concentration Ratio (CR)
4.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Non-Alcoholic Steatohepatitis (NASH) Drugs in 2021
4.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters, Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type
4.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters and Area Served
4.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Company
4.5.1 Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2020, 2021 & 2022)
5 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2028)
5.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017-2022
5.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Details
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.1.5 AstraZeneca Recent Development
7.2 Conatus Pharmaceuticals
7.2.1 Conatus Pharmaceuticals Company Details
7.2.2 Conatus Pharmaceuticals Business Overview
7.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.2.5 Conatus Pharmaceuticals Recent Development
7.3 Enzo Biochem
7.3.1 Enzo Biochem Company Details
7.3.2 Enzo Biochem Business Overview
7.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.3.5 Enzo Biochem Recent Development
7.4 Galmed Pharmaceuticals
7.4.1 Galmed Pharmaceuticals Company Details
7.4.2 Galmed Pharmaceuticals Business Overview
7.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.4.5 Galmed Pharmaceuticals Recent Development
7.5 Genfit
7.5.1 Genfit Company Details
7.5.2 Genfit Business Overview
7.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.5.5 Genfit Recent Development
7.6 Gilead
7.6.1 Gilead Company Details
7.6.2 Gilead Business Overview
7.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.6.5 Gilead Recent Development
7.7 Horizon Pharma
7.7.1 Horizon Pharma Company Details
7.7.2 Horizon Pharma Business Overview
7.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.7.5 Horizon Pharma Recent Development
7.8 Immuron
7.8.1 Immuron Company Details
7.8.2 Immuron Business Overview
7.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.8.5 Immuron Recent Development
7.9 Intercept Pharmaceuticals
7.9.1 Intercept Pharmaceuticals Company Details
7.9.2 Intercept Pharmaceuticals Business Overview
7.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.9.5 Intercept Pharmaceuticals Recent Development
7.10 Novo Nordisk
7.10.1 Novo Nordisk Company Details
7.10.2 Novo Nordisk Business Overview
7.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.10.5 Novo Nordisk Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Figures, Tables and Charts Available in Global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report & Forecast 2022-2028
List of TablesTable 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
Table 3. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Table 4. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 5. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Player, 2017-2022
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2021)
Table 15. Top Players of Non-Alcoholic Steatohepatitis (NASH) Drugs in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. AstraZeneca Company Details
Table 31. AstraZeneca Business Overview
Table 32. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 33. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 34. AstraZeneca Recent Development
Table 35. Conatus Pharmaceuticals Company Details
Table 36. Conatus Pharmaceuticals Business Overview
Table 37. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 38. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 39. Conatus Pharmaceuticals Recent Development
Table 40. Enzo Biochem Company Details
Table 41. Enzo Biochem Business Overview
Table 42. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 43. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 44. Enzo Biochem Recent Development
Table 45. Galmed Pharmaceuticals Company Details
Table 46. Galmed Pharmaceuticals Business Overview
Table 47. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 48. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 49. Galmed Pharmaceuticals Recent Development
Table 50. Genfit Company Details
Table 51. Genfit Business Overview
Table 52. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 53. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 54. Genfit Recent Development
Table 55. Gilead Company Details
Table 56. Gilead Business Overview
Table 57. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 58. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 59. Gilead Recent Development
Table 60. Horizon Pharma Company Details
Table 61. Horizon Pharma Business Overview
Table 62. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 63. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 64. Horizon Pharma Recent Development
Table 65. Immuron Company Details
Table 66. Immuron Business Overview
Table 67. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 68. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 69. Immuron Recent Development
Table 70. Intercept Pharmaceuticals Company Details
Table 71. Intercept Pharmaceuticals Business Overview
Table 72. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 73. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 74. Intercept Pharmaceuticals Recent Development
Table 75. Novo Nordisk Company Details
Table 76. Novo Nordisk Business Overview
Table 77. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 78. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
Table 79. Novo Nordisk Recent Development
Table 80. Research Programs/Design for This Report
Table 81. Key Data Information from Secondary Sources
Table 82. Key Data Information from Primary Sources
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Product Picture
Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size 2017-2028 (US$ Million)
Figure 4. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size 2017-2028 (US$ Million)
Figure 6. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share in Global 2017-2028
Figure 7. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 8. Product Picture of Vitamin E & Pioglitazone
Figure 9. Product Picture of Obeticholic Acid (OCA)
Figure 10. Product Picture of Elafibranor
Figure 11. Product Picture of Selonsertib & Cenicriviroc
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type in 2022 & 2028
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028) & (US$ Million)
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
Figure 15. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type in 2022 & 2028
Figure 16. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028) & (US$ Million)
Figure 17. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
Figure 18. Product Picture of Hospital Pharmacy
Figure 19. Product Picture of Online Provider
Figure 20. Product Picture of Retail Pharmacy
Figure 21. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2022 & 2028
Figure 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028) & (US$ Million)
Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
Figure 24. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2022 & 2028
Figure 25. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028) & (US$ Million)
Figure 26. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
Figure 27. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
Figure 28. U.S. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 29. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 30. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
Figure 31. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
Figure 37. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. Taiwan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Indonesia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Thailand Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Malaysia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Philippines Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
Figure 48. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 49. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
Figure 52. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. U.A.E Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 56. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 57. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 58. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 59. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 60. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 61. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 62. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 63. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 64. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Keyplayers in Global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report & Forecast 2022-2028
AstraZenecaConatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk